Cost-Effectiveness Assessment for an Orphan Drug in a Rare Autoimmune Disease
Client: A Leading Pharmaceutical Company Challenge:A pharmaceutical company sought to adapt a cost-effectiveness model for an orphan drug targeting a rare autoimmune disease. The goal was to determine the incremental cost-effectiveness ratio (ICER), estimate the budget impact, and assist the company in negotiating pricing and a capped contract for utilization within NHS hospitals. Solution Provided […]
Comparative Effectiveness of Treatment Options for Advanced Stage Cancer with Genetic Alterations to Support HTA
Client: A Leading Pharmaceutical Company Challenge:The client aimed to assess the efficacy and safety of a novel treatment (Drug A) in adult patients with advanced stage cancer harboring specific genetic alterations. The objective was to evaluate its effectiveness alongside standard chemotherapy and immunotherapy options in patients who had previously undergone systemic therapy. Solution Provided by […]